U.S. Markets close in 5 hrs 31 mins
  • S&P 500

    4,577.77
    +45.01 (+0.99%)
     
  • Dow 30

    35,313.46
    +284.81 (+0.81%)
     
  • Nasdaq

    14,577.57
    +237.32 (+1.65%)
     
  • Russell 2000

    2,076.11
    +13.32 (+0.65%)
     
  • Crude Oil

    86.94
    -0.02 (-0.02%)
     
  • Gold

    1,847.30
    +4.10 (+0.22%)
     
  • Silver

    24.61
    +0.38 (+1.58%)
     
  • EUR/USD

    1.1351
    +0.0004 (+0.0341%)
     
  • 10-Yr Bond

    1.8360
    +0.0090 (+0.49%)
     
  • Vix

    22.43
    -1.42 (-5.95%)
     
  • GBP/USD

    1.3648
    +0.0036 (+0.2675%)
     
  • USD/JPY

    114.0880
    -0.2650 (-0.2317%)
     
  • BTC-USD

    43,166.96
    +861.07 (+2.04%)
     
  • CMC Crypto 200

    1,022.69
    +27.43 (+2.76%)
     
  • FTSE 100

    7,558.78
    -30.88 (-0.41%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.

  • The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients.

  • Cassava Sciences' is conducting the Phase 3 program in Alzheimer's under Special Protocol Assessments (SPA) from the FDA.

  • The first Phase 3 RETHINK-ALZ study is designed to evaluate the safety and efficacy of oral simufilam 100 mg in enhancing cognition and slowing cognitive and functional decline over 52 weeks.

  • This study plans to enroll approximately 750 patients with mild-to-moderate Alzheimer's disease.

  • The Company commenced patient screening for RETHINK-ALZ in October 2021, followed by patient dosing in November 2021.

  • Recently, SEC launched a probe into claims that Cassava Sciences' manipulated data key to its case for simufilam.

  • Price Action: SAVA shares are up 0.57% at $47.34 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.